Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02293005 · OUTCOME

Overall Survival

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma · Source last updated 2022-10-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 35 months

What was measured

Overall Survival is defined as the time from the date of randomization to the date of death due to any cause.

Analysis population: 1 patient did not complete one cycle of treatment and 25 patients were evaluable for efficacy.

Groups in this outcome

Alisertib

Alisertib was administered PO at 50 mg BID for 7 days in each treatment cycle, followed by a 14-day, treatment-free period, for a 21-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Alisertib25

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Alisertib6.3Not reported5.711.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5.7
        upper Limit
        11.1
        value
        6.3
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
Overall Survival is defined as the time from the date of randomization to the date of death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Alisertib was administered PO at 50 mg BID for 7 days in each treatment cycle, followed by a 14-day, treatment-free period, for a 21-day cycle.
    id
    OG000
    title
    Alisertib
param Type
MEDIAN
population Description
1 patient did not complete one cycle of treatment and 25 patients were evaluable for efficacy.
reporting Status
POSTED
time Frame
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 35 months
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice